文献速递外周动脉疾病

下肢外周血管介入术后口服Xa因子抑制剂使用不足

Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention.
PubMed 文献 · J Vasc Surg · 2023-04-24

该回顾性横断面研究利用血管质量倡议外周血管介入注册数据(2018年1月至2022年6月),分析91,569例可能适合启动Xa因子抑制剂的外周血管介入术后患者。结果显示Xa因子抑制剂启动率从2018年的3.5%升至2022年的9.1%(P<.0001),但绝对率仍低,多数符合条件的患者未获处方。

要点

  • 外周血管介入术后Xa因子抑制剂启动率从2018年3.5%升至2022年9.1%(P<.0001)。
  • 非择期(OR 4.36)和急诊(OR 8.20)状态是Xa因子抑制剂启动的最强正向预测因素。
  • 术后双联抗血小板治疗处方是最强负向预测因素(OR 0.20),约70%患者出院时使用双联抗血小板治疗。

核心结论

  • 近年来外周血管介入术后Xa因子抑制剂启动率有所增加,但绝对率仍低,多数符合条件的患者未获处方该治疗。

研究设计与样本

  • 回顾性横断面研究,使用血管质量倡议外周血管介入注册数据,纳入2018年1月至2022年6月共91,569例可能适合启动Xa因子抑制剂的外周血管介入手术。
  • 采用多变量逻辑回归确定外周血管介入术后启动Xa因子抑制剂的预测因素,以比值比(OR)及95%置信区间(CI)报告。

主要发现

  • 外周血管介入术后Xa因子抑制剂启动率从2018年的3.5%上升至2022年的9.1%(P<.0001)。
  • 非择期状态(OR 4.36;95%CI 4.06-4.68;P<.0001)和急诊状态(OR 8.20;95%CI 7.14-9.41;P<.0001)是启动Xa因子抑制剂的最强正向预测因素。
  • 术后双联抗血小板治疗处方是最强负向预测因素(OR 0.20;95%CI 0.17-0.23;P<.0001)。
  • 抗血小板药物仍是最常见的外周血管介入术后抗血栓方案,约70%受试者出院时使用双联抗血小板治疗,约20%使用单联抗血小板治疗。

临床怎么用

  • 作者指出,术后双联抗血小板治疗处方与Xa因子抑制剂启动的负向关联突显了对外周血管介入术后采用双通路抑制的显著犹豫,以及VOYAGER PAD研究结果向临床实践转化有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients undergoing peripheral vascular intervention (PVI) (ie, endovascular revascularization) for symptomatic lower extremity peripheral artery disease remain at high risk for major adverse limb and cardiovascular events. High-quality evidence demonstrates the addition of a low-dose oral factor Xa inhibitor to single antiplatelet therapy, termed dual pathway inhibition (DPI), reduces the incidence of major adverse events in this population. This study aims to describe the longitudinal trends in factor Xa inhibitor initiation after PVI, identify patient and procedural characteristics associated with factor Xa inhibitor use, and describe temporal trends in antithrombic therapy post-PVI before vs after VOYAGER PAD. METHODS: This retrospective cross-sectional study was performed using data from the Vascular Quality Initiative PVI registry from January 2018 through June 2022. Multivariate logistic regression was utilized to determine predictors of factor Xa inhibitor initiation following PVI, reported as odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: A total of 91,569 PVI procedures were deemed potentially eligible for factor Xa inhibitor initiation and were included in this analysis. Overall rates of factor Xa inhibitor initiation after PVI increased from 3.5% in 2018 to 9.1% in 2022 (P < .0001). The strongest positive predictors of factor Xa inhibitor initiation after PVI were non-elective (OR, 4.36; 95% CI, 4.06-4.68; P < .0001) or emergent (OR, 8.20; 95% CI, 7.14-9.41; P < .0001) status. The strongest negative predictor was postoperative dual antiplatelet therapy prescription (OR, 0.20; 95% CI, 0.17-0.23; P < .0001), highlighting significant hesitation about use of DPI after PVI and limited translation of VOYAGER PAD findings into clinical practice. Antiplatelet medications remain the most common antithrombotic regimen after PVI, with almost 70% of subjects discharged on dual antiplatelet therapy and approximately 20% discharged on single antiplatelet therapy. CONCLUSIONS: Factor Xa inhibitor initiation after PVI has increased in recent years, although the absolute rate remains low, and most eligible patients are not prescribed this treatment.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bhuta S, Ariss RW, Ding L, et al. Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention. J Vasc Surg. 2023. PMID: 37100234. doi:10.1016/j.jvs.2023.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。